Literature DB >> 22205445

The role of breast MR imaging in pre-operative determination of invasive disease for ductal carcinoma in situ diagnosed by needle biopsy.

Mariko Goto1, Sachiko Yuen, Kentaro Akazawa, Kaori Nishida, Eiichi Konishi, Mariko Kajihara, Nobuhiko Shinkura, Kei Yamada.   

Abstract

OBJECTIVES: To evaluate whether magnetic resonance (MR) imaging features can predict the presence of occult invasion in cases of biopsy-proven pure ductal carcinoma in situ (DCIS).
METHODS: We retrospectively reviewed 92 biopsy-proven pure DCIS in 92 women who underwent MR imaging. The following MR imaging findings were compared between confirmed DCIS and invasive breast cancer (IBC): lesion size, type, morphological and kinetic assessments by ACR BI-RADS MRI, and findings of fat-suppressed T2-weighted (FS-T2W) imaging.
RESULTS: Sixty-eight of 92 (74%) were non-mass-like enhancements (NMLE) and 24 were mass lesions on MR imaging. Twenty-one of 68 (31%) NMLE and 13 of 24 (54%) mass lesions were confirmed as IBC. In NMLE lesions, large lesions (P = 0.007) and higher signal intensities (SI) on FS-T2W images (P = 0.032) were significantly associated with IBC. Lesion size remained a significant independent predictor of invasion in multivariate analysis (P = 0.032), and combined with FS-T2W SIs showed slightly higher observer performances (area under the curve, AUC, 0.71) than lesion size alone (AUC 0.68). There were no useful findings that enabled the differentiation of mass-type lesions.
CONCLUSIONS: Breast MR imaging is potentially useful to predict the presence of occult invasion in biopsy-proven DCIS with NMLE. KEY POINTS: MR mammography permits more precise lesion assessment including ductal carcinoma in situ A correct diagnosis of occult invasion before treatment is important for clinicians This study showed the potential of MR mammography to diagnose occult invasion Treatment and/or aggressive biopsy can be given with greater confidence MR mammography can lead to more appropriate management of patients.

Entities:  

Mesh:

Year:  2011        PMID: 22205445     DOI: 10.1007/s00330-011-2357-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  26 in total

1.  The finding of invasive cancer after a preoperative diagnosis of ductal carcinoma-in-situ: causes of ductal carcinoma-in-situ underestimates with stereotactic 14-gauge needle biopsy.

Authors:  Lidewij E Hoorntje; Marguerite E I Schipper; Petra H M Peeters; Frank Bellot; Remmert K Storm; Inne H M Borel Rinkes
Journal:  Ann Surg Oncol       Date:  2003-08       Impact factor: 5.344

2.  Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates.

Authors:  R J Jackman; F Burbank; S H Parker; W P Evans; M C Lechner; T R Richardson; A A Smid; H B Borofsky; C H Lee; H M Goldstein; K J Schilling; A B Wray; R F Brem; T H Helbich; D E Lehrer; S J Adler
Journal:  Radiology       Date:  2001-02       Impact factor: 11.105

3.  Segmental enhancement on breast MR images: differential diagnosis and diagnostic strategy.

Authors:  Sachiko Yuen; Takayoshi Uematsu; Kasami Masako; Yoshihiro Uchida; Tsunehiko Nishimura
Journal:  Eur Radiol       Date:  2008-05-20       Impact factor: 5.315

4.  Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging.

Authors:  Jennifer H Menell; Elizabeth A Morris; D David Dershaw; Andrea F Abramson; Edi Brogi; Laura Liberman
Journal:  Breast J       Date:  2005 Nov-Dec       Impact factor: 2.431

5.  Characterization of ductal carcinoma in situ on diffusion weighted breast MRI.

Authors:  Habib Rahbar; Savannah C Partridge; Peter R Eby; Wendy B Demartini; Robert L Gutierrez; Sue Peacock; Constance D Lehman
Journal:  Eur Radiol       Date:  2011-05-12       Impact factor: 5.315

6.  Ductal carcinoma in situ diagnosed with stereotactic core needle biopsy: can invasion be predicted?

Authors:  C H Lee; D Carter; L E Philpotts; M E Couce; L J Horvath; R C Lange; I Tocino
Journal:  Radiology       Date:  2000-11       Impact factor: 11.105

7.  Predictors of invasive disease in breast cancer when core biopsy demonstrates DCIS only.

Authors:  Mary F Dillon; Enda W McDermott; Cecily M Quinn; Ann O'Doherty; Niall O'Higgins; Arnold D K Hill
Journal:  J Surg Oncol       Date:  2006-06-01       Impact factor: 3.454

8.  Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer.

Authors:  Wendie A Berg; Lorena Gutierrez; Moriel S NessAiver; W Bradford Carter; Mythreyi Bhargavan; Rebecca S Lewis; Olga B Ioffe
Journal:  Radiology       Date:  2004-10-14       Impact factor: 11.105

9.  BI-RADS MRI enhancement characteristics of ductal carcinoma in situ.

Authors:  Eric L Rosen; Stacy A Smith-Foley; Wendy B DeMartini; Peter R Eby; Sue Peacock; Constance D Lehman
Journal:  Breast J       Date:  2007 Nov-Dec       Impact factor: 2.431

10.  Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures.

Authors:  M D Lagios; P R Westdahl; F R Margolin; M R Rose
Journal:  Cancer       Date:  1982-10-01       Impact factor: 6.860

View more
  7 in total

1.  Diffusion-tensor imaging as an adjunct to dynamic contrast-enhanced MRI for improved accuracy of differential diagnosis between breast ductal carcinoma in situ and invasive breast carcinoma.

Authors:  Yuan Wang; Xiaopeng Zhang; Kun Cao; Yanling Li; Xiaoting Li; Liping Qi; Lei Tang; Zhilong Wang; Shunyu Gao
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

2.  Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer?

Authors:  Michael R Harowicz; Ashirbani Saha; Lars J Grimm; P Kelly Marcom; Jeffrey R Marks; E Shelley Hwang; Maciej A Mazurowski
Journal:  J Magn Reson Imaging       Date:  2017-02-09       Impact factor: 4.813

3.  Radiopathological features predictive of involved margins in ductal carcinoma in situ.

Authors:  D M Layfield; H See; M Stahnke; L Hayward; R I Cutress; R S Oeppen
Journal:  Ann R Coll Surg Engl       Date:  2016-09-23       Impact factor: 1.891

4.  Features of occult invasion in biopsy-proven DCIS at breast MRI.

Authors:  Dorota Jakubowski Wisner; E Shelley Hwang; C Belinda Chang; Hilda H Tso; Bonnie N Joe; Juan N Lessing; Ying Lu; Nola M Hylton
Journal:  Breast J       Date:  2013 Nov-Dec       Impact factor: 2.431

5.  Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy.

Authors:  Hemei Zhou; Jing Yu; Xiaodong Wang; Kunwei Shen; Jiandong Ye; Xiaosong Chen
Journal:  Sci Rep       Date:  2022-02-09       Impact factor: 4.379

6.  Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment.

Authors:  K Takagi; T Ishida; Y Miki; H Hirakawa; Y Kakugawa; G Amano; A Ebata; N Mori; Y Nakamura; M Watanabe; M Amari; N Ohuchi; H Sasano; T Suzuki
Journal:  Br J Cancer       Date:  2013-06-11       Impact factor: 7.640

7.  Predictive factors for the presence of invasive components in patients diagnosed with ductal carcinoma in situ based on preoperative biopsy.

Authors:  Kwan Ho Lee; Jeong Woo Han; Eun Young Kim; Ji Sup Yun; Yong Lai Park; Chan Heun Park
Journal:  BMC Cancer       Date:  2019-12-10       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.